schizophrenia

News and resources

Month: January 2021

Jan 23 2021

Paranoid Schizophrenia: Signs and Treatment – Verywell Health

by Clinical Editor

No Comments

Paranoid Schizophrenia: Signs and Treatment Verywell Health

Jan 23 2021

Undifferentiated Schizophrenia: Definition, Symptoms, Traits, Causes, Treatment – Verywell Health

by Clinical Editor

No Comments

Undifferentiated Schizophrenia: Definition, Symptoms, Traits, Causes, Treatment Verywell Health

Jan 23 2021

Investigating new treatment for schizophrenia as first Psychiatry Consortium funded project announce

by Clinical Editor

No Comments

A partnership between the University of Oxford, Earlham Institute (EI), and global pharmaceutical companies Biogen Inc and Boehringer Ingelheim will investigate a promising new drug target for the …

Jan 23 2021

Increased risk of Parkinson’s disease in patients with schizophrenia

by Clinical Editor

No Comments

A new study conducted at the University of Turku, Finland, shows that patients with a schizophrenia spectrum disorder have an increased risk of Parkinson’s disease later in life. The increased...

Jan 23 2021

Psychiatric Nurses’ Perceptions of Therapeutic Alliance With the Schizophrenia Population: A Survey Study

by Clinical Editor

No Comments

Research on nurse–patient relationships with the schizophrenia population is sparse. The current study piloted a survey to explore therapeutic relationships. Fifty-one psychiatric nurses completed an …

Jan 23 2021

Parkinson’s disease may up schizophrenia risk: Study

by Clinical Editor

No Comments

Patients with a schizophrenia spectrum disorder have an increased risk of Parkinson’s disease later in life. The study indicates that the increased risk may be due to alterations in the...

Jan 23 2021

CAPLYTA® (lumateperone) Open-Label Safety Switching Study in Patients with Schizophrenia Published in the Journal, Schizophrenia Research

by Clinical Editor

No Comments

Patients with stable symptoms of schizophrenia were switched from previous antipsychotic medications with no dose titration to CAPLYTA 42 mg for …

Jan 22 2021

LAI paliperidone use during early schizophrenia phases linked to better outcomes – Healio

by Clinical Editor

No Comments

LAI paliperidone use during early schizophrenia phases linked to better outcomes Healio

Jan 22 2021

Exercise and Cognition in Schizophrenia: Is There a Link? – Psychiatric Times

by Clinical Editor

No Comments

Exercise and Cognition in Schizophrenia: Is There a Link? Psychiatric Times

Jan 22 2021

Peter Thiel-backed psychedelics start-up targets schizophrenia ahead of IPO

by Clinical Editor

No Comments

ATAI Life Science, a Peter Thiel-backed start-up, has taken a majority stake in Recognify, a company that is developing drugs to help treat schizophrenia.